跳至主要内容
临床试验/ACTRN12615000778583
ACTRN12615000778583尚未招募4 期

Investigating the effects of metformin on growth factors involved in prostate cancer progression in prostate cancer patients

Western Sydney Local Health District0 个研究点目标入组 26 人开始时间: 2015年7月27日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
入组人数
26

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
50 Years 至 80 Years(—)
性别
Male

入选标准

  • (1)Age 50 to 80 years
  • (2)ECOG equal or lower than 1
  • (3)Histologically confirmed prostate cancer of early or locally advanced stage, metastatic prostate cancer with bone involvement only
  • (4)Stable treatment with ADT in the form of a GnRH agonist for more than 6 months
  • (5)Able to understand and the willingness to sign a written informed consent document

排除标准

  • (1)Visceral metastases
  • (2)Castrate-resistant prostate cancer (PSA progression defined as at least 3 PSA rises, measured on three successive occasions more than 1 week apart after hormonal treatment)
  • (3)History of confirmed type 1 or type 2 diabetes mellitus
  • (4)Current or prior use of metformin or other diabetes mellitus treatment within the last year
  • (5)Known hypersensitivity or allergy to metformin or any of its excipients
  • (6)Hypothalamic or pituitary disorders
  • (7)Other forms of malignancies excluding prostate cancer
  • (8)Renal (eGFR < 60mL/min/1.73m2) or hepatic impairment (bilirubin > 1.5 x upper limit normal, ALT and ALP > 2.5x upper limit normal)
  • (9)History of lactic acidosis
  • (10) Cardiac or respiratory insufficiency, alcohol abuse, severe infections that are likely to increase the risk of lactic acidosis
  • (11) Any medications known to cause interference with the endocrine system (excluding ADT)
  • (12) Medical or psychiatric conditions that compromise the patient’s ability to give informed consent

研究者

相似试验